Biguanides Market Report 2026

Biguanides Market Overview

• Biguanides market size has reached to $5.11 billion in 2025 • Expected to grow to $5.97 billion in 2030 at a compound annual growth rate (CAGR) of 3.1% • Growth Driver: Impact Of Rising Diabetes Prevalence On Biguanides • Market Trend: Advancements In Extended-Release Biguanides For Enhanced Diabetes Management • Asia-Pacific was the largest region in 2025 and Middle East is the fastest growing region.

What Is Covered Under Biguanides Market?

Biguanides refer to a group of medications primarily used to treat type 2 diabetes. They help lower blood sugar levels by reducing the amount of sugar produced by the liver and improving the body's response to insulin. These medications are also used to treat polycystic ovary syndrome (PCOS) and other metabolic disorders. The main types of biguanides are metformin, phenformin, and others. Metformin is a widely used biguanide medication that is used to treat type 2 diabetes by lowering blood sugar levels. Various dosage forms, including tablets and oral solutions in different formulations, such as immediate-release and extended-release, are provided through a variety of distribution channels, which include hospital pharmacies, retail pharmacies, and online pharmacies.

What Is The Biguanides Market Growth Forecast?

The biguanides market size is expected to see steady growth in the next few years. It will grow to $5.97 billion in 2030 at a compound annual growth rate (CAGR) of 3.1%. The growth in the forecast period can be attributed to growing demand for personalized medicine, expansion of telemedicine for diabetes care, rising incidence of pcOS, development of combination therapies, government initiatives promoting chronic disease management. Major trends in the forecast period include personalized diabetes management solutions, combination therapy development, expanded indications beyond type 2 diabetes, home healthcare & remote patient monitoring, cost-effective generic biguanides.

Global Biguanides Market Segmentation

1) By Type: Metformin, Phenformin, Other Types 2) By Dosage Form: Tablets, Oral Solutions 3) By Formulation: Immediate Release, Extended Release 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies Subsegments: 1) By Metformin: Immediate-Release Metformin, Extended-Release Metformin 2) By Phenformin: Phenformin Hydrochloride 3) By Other Types: Buformin, Metformin Combinations

What Is The Driver Of The Biguanides Market?

The rise in diabetes is expected to propel the growth of the biguanides market going forward. Diabetes is a chronic metabolic disorder characterized by elevated blood glucose levels due to insufficient insulin production or impaired insulin function. The rise in diabetes is driven by lifestyle changes, population aging, and increased diagnostic awareness. The biguanides market supports diabetes management by improving insulin sensitivity, reducing hepatic glucose production, and helping lower blood sugar levels in individuals with type 2 diabetes. For instance, in March 2024, according to the Office for Health Improvement & Disparities (OHID), a UK-based government department, between March 2022 and March 2023, the percentage of individuals with type 1 diabetes receiving all eight recommended care processes increased by 22%, while for type 2 diabetes it increased by 21%, and the proportion achieving target HbA1c levels reached 37.9%, the highest value ever reported. Therefore, the rising prevalence of diabetes is driving the growth of the biguanides industry.

Key Players In The Global Biguanides Market

Major companies operating in the biguanides market are Pfizer Inc., Sanofi-Aventis LLC, Viatris Inc., Aurobindo Pharma Ltd., Cipla Ltd, Dr. Reddy's Laboratories, Lupin Limited, Zydus Lifesciences Limited, Torrent Pharmaceuticals Limited, Intas Pharmaceuticals Ltd., Apotex Inc, Sun Pharmaceutical Industries Ltd., Glenmark Pharmaceuticals Ltd., Mylan Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Alkem Laboratories Ltd., Panacea Biotech Ltd., Wanbury Ltd, USV Private Limited, Abbott Laboratories

Global Biguanides Market Trends and Insights

Major companies operating in the biguanide market are focusing on developing advanced solutions such as extended-release biguanide formulations to improve patient compliance, enhance glycemic control, and minimize gastrointestinal side effects. Extended-release biguanide formulations refer to medications designed to release their active component gradually over time, maintaining stable blood concentrations, improving tolerability, and supporting better long-term adherence in individuals managing diabetes. For instance, in August 2023, Dr. Reddy’s Laboratories, an India-based biotechnology company, launched saxagliptin and metformin hydrochloride extended-release tablets, a USFDA-approved generic version of KOMBIGLYZE XR that combines saxagliptin, a DPP-4 inhibitor, with metformin, a biguanide, offering adults with type 2 diabetes mellitus an effective once-daily treatment option that supports improved glycemic control when used alongside diet and exercise while enhancing adherence through its extended-release design.

What Are Latest Mergers And Acquisitions In The Biguanides Market?

In August 2023, Lupin, an India-based biopharmaceutical company, acquired the diabetes brands ONDERO and ONDERO MET from Boehringer Ingelheim for an undisclosed amount. This acquisition strengthens Lupin’s position in the anti-diabetes segment by expanding its product portfolio with established oral antidiabetic therapies. It further enhances the company’s ability to improve patient access to essential diabetes medications and reinforces its competitive presence in the metabolic disorders market. Boehringer Ingelheim is a Germany-based biopharmaceutical company engaged in the research, development, and production of therapies for human and veterinary medicine.

Regional Insights

Asia-Pacific was the largest region in the biguanides market in 2025. Middle East And Africa is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Biguanides Market?

The biguanides market consists of sales of Chlorhexidine, Polyhexanide, Proguanil, and Buformin. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Biguanides Market Report 2026?

The biguanides market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the biguanides industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.